Research programme: encapsulated methionine gamma lyase - ERYtech Pharma

Drug Profile

Research programme: encapsulated methionine gamma lyase - ERYtech Pharma

Alternative Names: ERY-MET; erythrocyte encapsulated methionine γ lyase

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator ERYtech Pharma
  • Class Antineoplastics; Carbon sulfur lyases
  • Mechanism of Action Amino-acid-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Jan 2017 Pharmacodynamics data from preclinical studies in Cancer released by ERYtech phar
  • 28 Sep 2015 ERYtech plans a phase I trial for Cancer
  • 09 Apr 2014 Preclinical trials in Cancer in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top